Mucopolysaccharidoses are rare inherited metabolic disorders that may benefit from haematopoietic stem cell transplantation (HSCT) in selected cases. The aim of the procedure is to provide a number of stem cells that are capable of migrating into tissues and restoring the lacking enzymatic activity. Any GvHD is undesirable, and the graft should contain committed or differentiated cells, to protect against infections in the earliest aplastic phase. TCRαβ and CD19 depletion is a stem cell manipulation technique that allows preservation of residual cells and GvHD prevention through removal of alloreactive lymphocytes. We report here our experience with this approach in a patient with Hurler syndrome (HS).
A 21-month-old male child was referred to our institution with a clinical and biochemical diagnosis of mucopolysaccharidosis type I (HS) made in Iraq at the age of 1 year. He presented with macrocephaly, short neck, significant skeletal impairment, mild hepatosplenomegaly and umbilical hernia. His psychomotor development assessment showed a global significant retardation including the inability to walk independently and talk (score on Bayley scales o50, probably influenced by cultural and linguistic diversities). Audiometric examination documented a hearing threshold of 70 dB without lateralization. Urinary glycosaminoglycan (GAG) baseline levels were 637.9 mg GAGs per gram creatinine (normal values 13-62). Enzymatic activity on lymphocytes was absent. Molecular diagnosis was performed, showing a homozygous p.Tyr202 term (exon 6:c.606C4G) mutation of the alpha-L-iduronidase gene.
Soon after that, the patient was initiated on enzymereplacement therapy (ERT), specifically weekly infusions of 0.58 mg/kg recombinant alpha-iduronidase enzyme (laronidase, Genzyme Corporation, Cambridge, MA, USA).
Six months after the beginning of ERT, HSCT from matched unrelated donor was performed. Myeloablative conditioning regimen consisted of fludarabine, treosulfan, melphalan and anti-thymocyte globulin. The source of stem cells was peripheral blood, and the graft was TCRαβ and CD19 depleted. A total number of 1.25 × 10 9 /kg nucleated cells and 37 × 10 6 /kg CD34+ cells were infused. A total of 0.032766 × 10 6 /kg TCRαβ T cells were co-infused with the graft.
Immunoprophylaxis with mycophenolate mofetil was discontinued o 2 months after HSCT owing to the low risk of GvHD. Engraftment occurred on days +14 for neutrophils and +10 for platelets.
Post-HSCT course was complicated by an episode of tachycardia during anti-arrhythmic therapy (with spontaneous recovery), mild gastrointestinal GvHD presenting with vomiting and diarrhoea, and asymptomatic CMV reactivation 1 month after HSCT, responsive to IV antiviral therapy.
ERT was reinitiated immediately following HSCT and was continued for a total of 12 weeks.
The patient's response to treatment was impressive especially as far as motor and neurocognitive development was concerned: 6 months after beginning of ERT he was able to walk independently and 8 months after HSCT (14 months after beginning of ERT) his gait was normal, he could catch objects and his score on the Bayley scales was normal for his age. Auditory function assessment documented lateralization at 30 dB on the right and 40 dB on the left. Magnetic resonance imaging scan of the brain and cervical spine was performed before and after HSCT, showing the underlying disease's typical features without significant variations. Urinary GAG level 14 months after HSCT was 301.7 mg GAGs per gram creatinine, and enzymatic activity 6 months after HSCT was within the normal range. Skeletal anomalies and mild organomegaly persisted, but they were not associated with functional impairment. At the present time, 20 months after HSCT, the patient is in good clinical condition, with sustained engraftment and full donor chimerism.
In a few inborn errors of metabolism, including HS, HSCT has been shown to be beneficial by arresting the clinical progression of the disease and by reversing most of its clinical features, although the degree of improvement and residual disease burden are variable according to several factors, related either to the patient (that is, age) or to the transplant procedure's features. [1] [2] [3] The underlying rationale is the so-called 'cross-correction': the graft contains haematopoietic and mesenchymal stem cells that could differentiate into different tissue cells. Deficient enzyme production by neighbouring healthy cells can restore the deficit in affected cells.
HSCT has been performed for HS since 1980, using different stem cell sources.
The main problems associated with HSCT in these patients are the toxicity of the conditioning regimen, the risk of graft rejection and GvHD.
Some concerns are being raised regarding siblings who may be carriers of the defect and have abnormal enzymatic activity. In children lacking an HLA-matched related donor, a search for matched alternative donors should be started. In such cases, a widely used stem cell source is umbilical cord blood (UCB), given its prompt availability and the less-stringent HLA matching requirement.
The Kurtzberg and the Duke University Group reported encouraging results in their 20-patient case studies in terms of overall survival and neurocognitive outcome, strongly supporting such an approach. However, the use of UCB is associated with a delayed engraftment and an increased risk of infections in the early phases. In the previously mentioned case studies, all deaths were related to infectious complications. 4 Moreover, the donor is no further available for any adoptive immunotherapy approach.
Other stem cell sources include bone marrow and PBSC. In many European transplant centres, different donors and stem cell sources have been exploited. A retrospective survival analysis by Boelens et al. 5 showed superiority of a 10/10 unrelated donor (UD) if compared with a mismatched UCB HSCT (which is often the case).
As previously mentioned, graft rejection is a major concern: as reviewed by Rovelli 6 and Boelens, 5 many patients with HS may undergo a second or third HSCT. This further increases mortality, given the high comorbidity rate. Mixed chimerism is a common situation after HSCT for HS, as reported for the protocol MPS-HCT 2005 designed by the German Cooperative Group. 7 Sauer et al.
able to fully restore donor-derived haematopoiesis in patients in whom it was performed. GvHD is known to associate with a poorer global and neuropsychological outcome, as it can worsen the neurological damage owing to the underlying condition through demyelinating effects that eventually may be seen. 8, 9 Many strategies are currently available for GvHD prevention, either pharmacological (in vivo) or graft-engineering based (ex vivo): among them, one of the most effective is graft allodepletion, that is, the removal of T lymphocytes responsible for GvHD, which may be obtained either through positive selection of CD34+ cells or negative selection and removal of T lymphocytes. Gaipa et al. 10 reported the feasibility and safety of allodepletion through CD34+ selection in the setting of allogeneic HSCT in six children with inherited metabolic diseases, using the CliniMacs system (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). None of the patients developed GvHD. 10 Grigull et al. 11 reported a similar experience in five patients with HS, three of whom received donor's lymphocytes infusions to prevent graft rejection in a situation of mixed chimerism. Sauer et al., 12 monoclonal Ab T10B9; 1-31A and rabbit serum C′; anti-CD2 Ab and rabbit serum C′; soybean agglutination; and sheep RBC rosetting. 13 In the latter case, acute GvHD incidence rate of 55% was reported.
We report here an example of GvHD prevention using TCRαβ CD19 depletion in a case of HSCT for HS. This procedure has been developed in the setting of haploidentical HSCT, showing promising results in terms of engraftment and immunoreconstitution compared with other techniques. We thought such an approach could be suitable to non-oncological diseases also in the setting of unrelated donors.
In particular, as our patient did not have any HLA-matched siblings, we decided to use matched unrelated donor PBSC and TCRαβ CD19 depletion with the aim of obtaining a 'mega-dose' of stem cells, decreasing the risk of graft rejection and mixed chimerism. Removal of either T lymphocytes potentially responsible for GvHD and B lymphocytes involved in EBV infection was effective in preventing GvHD and severe infections, which are a problem in the UCB setting. The co-infusion of residual cells such as dendritic and natural killer cells, monocytes, γδ-lymphocytes, and committed myeloid and lymphoid precursors, which are not preserved in CD34+ positive selection, helped a rapid engraftment and immune recovery. Neutrophils and platelets engraftment occurred earlier than what is reported with other stem cell sources (day +14 vs day +24 and day +18, and day +10 vs day +56 and day +23, if compared with UCB data of the Duke University Group and to CD34+ positive selected HSCT performed by the German group, respectively). As for immune reconstitution, CD3+, CD4+, CD8+ and CD19+ cell recovery (defined as reaching the 10th percentile of age-matched reference values) occurred about 14 months after HSCT. The patient never needed IV Igs replacement. This compares favourably to what has been observed in already reported cases. 14, 15 The striking clinical improvement we observed needs corroboration by a longer follow-up and a larger number of cases, but encourages us to exploit this allodepletion strategy with patients at high risk of graft rejection and in whom GvHD is undesirable.
